<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375648</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446EFR08</org_study_id>
    <nct_id>NCT00375648</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer</brief_title>
  <acronym>TRAPEZE</acronym>
  <official_title>Assessment of the Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered
      intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients
      with prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to measure the intensity of the pain relief of the patients at the end of treatment with a five classes score (TOTPAR = TOTal PAin Relief)</measure>
    <time_frame>at 12 weeks or at 16 weeks (end of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the intensity of the pain relief of the patients with the PAR at each visit</measure>
    <time_frame>every 3 or 4 weeks during 12 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pain variation with VAS between V1 and V2, V3, V4, V5.</measure>
    <time_frame>every 3 or 4 weeks during 12 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pain variation with BPI (=Brief Pain Inventory) and correlate with VAS (=Visual Analog Scale)</measure>
    <time_frame>every 3 or 4 weeks during 12 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the use of analgesic (analgesic score) and the number of patients needing an analgesic radiotherapy between V1 and V5</measure>
    <time_frame>every 3 or 4 weeks during 12 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the duration of responses</measure>
    <time_frame>at 12 weeks or at 16 weeks (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the number of skeletal related events by patient</measure>
    <time_frame>every 3 or 4 weeks during 12 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect on functional disability, professional activity (BPI), the PS and overall condition (VAS) between V1 and V5</measure>
    <time_frame>every 3 or 4 weeks during 12 to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the variations of PSA (=Prostate specific Antigen) between V1 and End of study or premature withdrawal</measure>
    <time_frame>at 12 weeks or at 16 weeks (end of treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>zoledronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <arm_group_label>zoledronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven adenocarcinoma of the prostate

          -  Bone-scan documented metastases

          -  Age &gt; 18 years

          -  Non-controlled bone pain despite systemic anti-tumor therapy (hormone or chemotherapy)
             initiated at least 4 weeks before inclusion

          -  Life expectancy &gt; 3 months

          -  Written informed consent

        Exclusion Criteria:

          -  New systemic anti-tumor therapy initiated less than 4 weeks before study entry or
             predictable need for starting a new treatment within 8 weeks

          -  Radiation therapy on bone target lesions or bone-targeted isotope therapy (strontium
             or samarium) completed less than 4 weeks before study entry

          -  Bisphosphonate therapy within 8 weeks before study entry

          -  Abnormal renal function (serum creatinine &gt; 2 x the upper normal limit or creatinine
             clearance &lt; 30 ml/min)

          -  Corrected serum calcium &gt; 3 mmol/L or &lt; 2 mmol/L

          -  Clinically relevant hypersensitivity to zoledronic acid, or another bisphosphonate, or
             one component present in the formulation of the study drug

          -  Severe concomitant medical condition that could hamper patient's quality of life or
             influence the interpretation of pain

          -  Patients unable to fill in a questionnaire (neurologic or psychiatric conditions,
             illiteracy, etc.)

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4262</url>
    <description>Results for CZOL446EFR08 from Novartis Clinical Trials website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2006</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Bone metastases</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Bone metastases-related pain</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

